MTOR and Hyperglycemia: EVs derived from hyperglycemia-induced activated platelets act on the mammalian target of rapamycin (mTOR) pathway in glomerular ECs to exacerbate glomerular endothelial damage and albumin leakage in urine, promoting the development of DN at an early stage [107].